Turtle Creek Wealth Advisors LLC Buys 1,089 Shares of Stryker Corporation $SYK

Key Points

• Turtle Creek Wealth Advisors LLC increased its stake in Stryker Corporation by 6.3%, holding a total of 18,395 shares valued at approximately $7.28 million.
• Insider trading included significant sales, with Director Ronda E. Stryker selling 200,000 shares worth $75.29 million on August 6, indicating a 5.84% decrease in ownership.
• Analysts have mixed ratings for Stryker, with 15 Buy ratings and 6 Hold ratings, and a current average price target of $431.76.

Turtle Creek Wealth Advisors LLC increased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 6.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,395 shares of the medical technology company's stock after buying an additional 1,089 shares during the quarter. Turtle Creek Wealth Advisors LLC's holdings in Stryker were worth $7,278,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Mar Vista Investment Partners LLC lifted its position in Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after buying an additional 8,353 shares during the last quarter. United Services Automobile Association bought a new stake in shares of Stryker during the first quarter worth $2,857,000. AXS Investments LLC lifted its position in shares of Stryker by 13.7% during the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company's stock worth $3,286,000 after purchasing an additional 1,062 shares during the last quarter. Park Edge Advisors LLC bought a new stake in shares of Stryker during the second quarter worth $679,000. Finally, Hendley & Co. Inc. lifted its position in shares of Stryker by 60.3% during the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company's stock worth $5,546,000 after purchasing an additional 5,274 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Rothschild & Co Redburn assumed coverage on Stryker in a research report on Thursday, September 18th. They set a "neutral" rating and a $420.00 target price for the company. Wall Street Zen downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. BTIG Research lifted their target price on Stryker from $407.00 to $408.00 and gave the stock a "buy" rating in a research report on Monday. Evercore ISI decreased their target price on Stryker from $418.00 to $410.00 and set an "outperform" rating for the company in a research report on Tuesday, October 7th. Finally, Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $431.76.

Stryker Stock Performance

Shares of Stryker stock opened at $369.60 on Thursday. The firm has a market cap of $141.30 billion, a P/E ratio of 48.95, a P/E/G ratio of 2.67 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock's fifty day moving average price is $379.60 and its 200-day moving average price is $378.78.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the previous year, the firm earned $2.81 earnings per share. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's payout ratio is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.